Altre lingue Hansa Biopharma AB (publ)

Azioni

HNSA

SE0002148817

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 17:29:59 08/12/2023			Variaz. 5gg	Var. 1 gen.
23,42 ^SEK	+1,47%		-8,16%	-52,42%

07/12	Hansa Biopharma annuncia dati positivi di alto livello dallo studio di fase 2 15-HMedIdeS-09	CI
05/12	Hansa Biopharma prevede un risparmio annuale fino a 85 milioni di corone svedesi dal piano di riduzione della forza lavoro	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Hansa Biopharma - Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 Trial in Guillain-Barre Syndrome	08/12
Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)	07/12
Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial	07/12
Hansa Biopharma Expects Up to SEK85 Million Annual Savings from Workforce Reduction Plan	05/12
Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables	05/12
Sweden's Hansa Biopharma CFO to Depart in February 2024	27/11
Hansa Biopharma announces planned departure of Chief Financial Officer Donato Spota	27/11
Hahansa Biopharma AB Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024	27/11
Hansa Biopharma Q3 update - Slow progress ahead of 2024	27/10
Hansa Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/10
Hansa Biopharma Interim Report January-September 2023	26/10
Hansa Biopharma - Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study	18/10
Hansa Biopharma's Follow-up Study Shows High Survival Rate for Imlifidase-enabled Kidney Transplant Patients	17/10
Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study	17/10
Hansa Biopharma Announces Results from an Extended Pooled Analysis Using Data from the 17-Hmedides-14 Study, an International Long-Term Follow-Up Study of Patients Who Have Received A Kidney Transplant Following Desensitization with Imlifidase, Showing Sustained Positive Outcomes Out to 5 Years in the Majority of Highly Sensitized Patients Who Received an Imlifidase-Enabled Kidney Transplant	17/10
Hansa Biopharma - Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients	12/10
Hansa Biopharma to Finalize Randomization in Late-stage Kidney Study by Mid-2024	12/10
Hansa Biopharma Provides Clinical Pipeline Update on Confides Trial	11/10
Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients	11/10
Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients	11/10

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Transcript Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Hansa Biopharma AB (publ)

Azioni

HNSA

SE0002148817

Altre lingue

Filtri